BRISTOL MYERS SQUIBB

Tasca Therapeutics announced a $52M Series A financing led by Regeneron Ventures and Cure Ventures, with Invus Group participating. Funds will advance CP-383 into Phase 1/2 clinical studies and expand Tasca's drug pipeline. CP-383, a first-in-class molecule, shows promise across multiple cancers. Tasca's platform identifies druggable targets via auto-palmitoylation mapping.

The IDH market is set to grow rapidly due to expanded indications for approved therapies and increased R&D. Key players like Servier and Bayer are developing novel IDH inhibitors, with IDHIFA (enasidenib) being the first-in-class oral targeted inhibitor for IDH2-mutated AML. IDH inhibitors, including TIBSOVO (ivosidenib) and REZLIDA (enasidenib), are FDA and EMA-approved for various cancers. Vorasidenib, in advanced development, aims to treat IDH-mutant diffuse glioma. The market growth is driven by advancements in research and expanding pipeline of IDH inhibitors.

GSK's Blenrep, a multiple myeloma drug, shows significant overall survival benefit in a Phase 3 study, potentially becoming a new standard of care treatment. The drug, an antibody drug conjugate targeting BCMA, demonstrated a 42% reduction in the risk of death compared to a standard regimen. Despite initial market withdrawal, new data supports its efficacy in earlier treatment lines, with ongoing FDA review expected in July.

The global AI in Clinical Trials market is projected to grow from USD 1.42 billion in 2023 to USD 8.5 billion by 2035, at a CAGR of 16%. AI integration aims to streamline clinical trials by optimizing trial design, patient recruitment, and data analysis, addressing challenges like high costs and trial failures. Key drivers include venture capital funding and partnerships, with oncological disorders leading in AI application. The market is segmented by trial phase, therapeutic area, and geography, with Asia-Pacific currently dominating.

Insomnia market report forecasts growth from 2020 to 2034, driven by increasing prevalence, awareness, and emerging therapies like Seltorexant and TS-142. Challenges include high treatment costs and patient non-compliance, with unmet needs for long-term solutions with minimal side effects.

The GMMG-HD7 trial evaluated isatuximab (Isa) combined with lenalidomide, bortezomib, and dexamethasone (RVd) in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation (ASCT). Results showed significantly higher minimal residual disease negativity (MRDneg) rates with Isa-RVd (66%) compared to RVd alone (48%) after induction therapy, and higher continued MRDneg rates during maintenance therapy. The addition of Isa enhanced MRDneg rates and improved progression-free survival (PFS) outcomes, with MRDneg status being a significant prognostic factor for PFS. The trial demonstrated that Isa-RVd improves MRDneg rates and provides long-term benefits, particularly for patients maintaining MRDneg status throughout treatment.

Adenosine antagonists market growth driven by R&D in neurodegenerative diseases, oncology, and cardiovascular disorders. Innovations in formulation and delivery systems enhance efficacy and safety, increasing adoption. Key companies include Arcus Biosciences, Corvus Pharmaceuticals, Portage Biotech, Palobiofarm, iTeos Therapeutics. Promising drugs like Etrumadenant, Ciforadenant, PORT-6, and Inupadenant are in various clinical trial phases.

Optum Rx prefers Amgen’s Amjevita over Sandoz’s Hyrimoz and Cyltezo on its 2025 commercial formularies, aiming to reduce costs and improve affordability. Humira remains on the formulary but with stricter controls. Biosimilars, including Humira’s, have struggled with adoption despite cost savings potential. Optum Rx also adds and removes various oncology and CNS medications for 2025.

Optum Rx prefers Amgen’s Amjevita over Sandoz’s Hyrimoz and Cyltezo on its 2025 commercial formularies, aiming to reduce costs and improve affordability. Humira remains on the formulary but is subject to prior authorization. Biosimilars have struggled with low adoption despite cost advantages, but large PBMs like CVS Health are shifting towards biosimilars. Optum Rx also adds and removes various oncology and CNS medications from its 2025 formulary.

The phase III IMROZ trial found that adding isatuximab to bortezomib, lenalidomide, and dexamethasone (VRd) significantly reduced disease progression or death by 40% and doubled sustained MRD negativity rates in transplant-ineligible newly diagnosed multiple myeloma patients ≤ 80 years old, establishing isatuximab/VRd as a new standard of care.